TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 766340

Group type: EXPERIMENTAL
Intervention: Daily rifampicin plus ethambutol (ER7)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Twice-weekly rifampicin plus ethambutol (ER2)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Once-weekly rifampicin plus ethambutol (ER1)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Daily for 2 months and then once-weekly rifampicin plus ethambutol (ER7ER1)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Standard retreatment regimen of daily ethionamide plus pyrazinamide plus cycloserine (EtZC)
Number of subjects: 575
Study: 30659739

Group type: EXPERIMENTAL
Intervention: Dyadic yoga (DY)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 26
Study: 28427086

Group type: EXPERIMENTAL
Intervention: Self-sampling for HPV-testing (intervention group)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Liquid-based cytology performed by a health-care provider (control group)
Number of subjects: 667
Study: 25605528

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized JCP extract for five months over the pollen season
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 23490237

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 21816071

Group type: EXPERIMENTAL
Intervention: 3.0 g n‐3 LC‐PUFA/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3.2 g γ‐linolenic acid/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.6 g n‐3 LC‐PUFA + 1.8 g γ‐linolenic acid/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3.0 g olive oil
Number of subjects: 60
Study: 19143687

Group type: EXPERIMENTAL
Intervention: Trained anaesthetic technician
Number of subjects: 10

Group type: COMPARATOR
Intervention: Theatre nurse without training
Number of subjects: 10
Study: 18473961

Group type: EXPERIMENTAL
Intervention: High dose cytarabine with or without etoposide or mitoxantrone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timed sequential chemotherapy regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth factors to increase leukaemia cell sensitivity
Number of subjects: 0
Study: 15267080

Group type: EXPERIMENTAL
Intervention: Nicotine (21-mg transdermal patch)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study: 10673253

Group type: EXPERIMENTAL
Intervention: beta-blockers
Number of subjects: 869
Study: 9085324

Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF) dosing of vecuronium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard clinical assessment dosing of vecuronium
Number of subjects: 20
Study: 8435994

Group type: EXPERIMENTAL
Intervention: Shared care
Number of subjects: 206

Group type: COMPARATOR
Intervention: General practitioner care
Number of subjects: 206

Group type: COMPARATOR
Intervention: Conventional clinic care
Number of subjects: 206
Study: 30137217

Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 27163498

Group type: EXPERIMENTAL
Intervention: Delayed-release gastroresistant formulation of ketoprofen under fed conditions
Number of subjects: 16

Group type: COMPARATOR
Intervention: Delayed-release gastroresistant formulation of ketoprofen under fasting conditions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Comparison of Cmax/AUC between sexes
Number of subjects: 16
Study: 24445100

Group type: EXPERIMENTAL
Intervention: Targeted screening and education intervention by general practitioners, including skin examination and counseling with information leaflets.
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Targeted screening and education intervention by general practitioners.
Number of subjects: 173
Study: 22781424

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) for patients with LBBB
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) for patients without LBBB
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Change in QRS duration with CRT pacing
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: QRS duration
Number of subjects: 610
Study: 20159726

Group type: EXPERIMENTAL
Intervention: NPPV therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 50
Study: 18316137

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 16062002

Group type: EXPERIMENTAL
Intervention: Clinical practice guidelines for fracture prevention and osteoporosis management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidance and education for public health nurses and nutritionists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preventive measures against fractures and osteoporosis
Number of subjects: 0
Study: 12814146

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 7-10 days
Number of subjects: 1373

Group type: COMPARATOR
Intervention: Comparator antibacterials (amoxicillin 1000 mg three-times daily, clarithromycin 500 mg twice daily, trovafloxacin 200 mg once daily)
Number of subjects: 1373
Study: 10583454

Group type: EXPERIMENTAL
Intervention: Proximal jejunal feeding
Number of subjects: 8

Group type: COMPARATOR
Intervention: Distal jejunal feeding
Number of subjects: 8
Study: 8607489

Group type: EXPERIMENTAL
Intervention: Triple therapy with omeprazole 20 mg b.i.d. plus amoxicillin 1 g b.i.d. and azithromycin 500 mg mane (for the first 3 days)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Double therapy with omeprazole 20 mg b.i.d. plus amoxicillin 1 g t.i.d.
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Double therapy
Number of subjects: 92
Study: 1898142

Group type: EXPERIMENTAL
Intervention: Magnesium therapy (178 mEq over the first 4 postoperative days)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 6359047

Group type: EXPERIMENTAL
Intervention: Vidarabine 15 mg/kg/d
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Vidarabine 30 mg/kg/d
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Vidarabine (both dosages)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group from prior trial
Number of subjects: 39
Study: 31589553

Group type: EXPERIMENTAL
Intervention: Insulin Resistance (IR) prevalence measurement
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Body fat percentage measurement
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Family history of Type 2 diabetes mellitus (T2DM)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Edema
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Proteinuria
Number of subjects: 230
Study: 29401328

Group type: EXPERIMENTAL
Intervention: Statin treatment under ACC/AHA guidelines
Number of subjects: 1000
Study: 27066779

Group type: EXPERIMENTAL
Intervention: Web-based computer tailored intervention for physical activity action planning
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Web-based computer tailored intervention for fruit and vegetable action planning
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Web-based computer tailored intervention
Number of subjects: 346
Study: 24381222

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS)
Number of subjects: 1926

Group type: EXPERIMENTAL
Intervention: Reduction in maternal log TfR
Number of subjects: 1926

Group type: EXPERIMENTAL
Intervention: Increase in maternal hemoglobin
Number of subjects: 1926

Group type: COMPARATOR
Intervention: No LNS
Number of subjects: 1926
Study: 23153188

Group type: EXPERIMENTAL
Intervention: C-seal
Number of subjects: 616

Group type: COMPARATOR
Intervention: Control
Number of subjects: 616
Study: 20216022

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance for upper extremity blocks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance for lower extremity blocks
Number of subjects: 24
Study: 17595230

Group type: EXPERIMENTAL
Intervention: 6948 lead (6.6 Fr. Sprint Fidelis)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 6949 lead (6.6 Fr. Sprint Fidelis)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Larger leads (Models 6942, 6943, 6944, 6947, and 4074)
Number of subjects: 159
Study: 16281429

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Plasmapheresis
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Bayesian normal-normal model
Number of subjects: 160
Study: 12002292

Group type: EXPERIMENTAL
Intervention: Dilation and curettage (D & C)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Gonadotropin‐releasing hormone analogue (GnRHa) for 1 month
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Gonadotropin‐releasing hormone analogue (GnRHa) for 3 months
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Danazol for 3 months
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 15 mg for 3 months
Number of subjects: 131
Study: 9653613

Group type: EXPERIMENTAL
Intervention: Reduced-dose lispro before dinner (20% reduction) and increased NPH at bedtime (125% of usual dose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Usual-dose lispro plus usual-dose NPH before dinner
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard premeal human regular insulin and pre-bedtime NPH insulin (control)
Number of subjects: 13
Study: 8593015

Group type: EXPERIMENTAL
Intervention: 1,000 mg oral valaciclovir
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1,000 mg [14C]valaciclovir
Number of subjects: 12
Study: 2569686

Group type: EXPERIMENTAL
Intervention: OKY-046 80 mg (L group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OKY-046 400 mg (H group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (P group)
Number of subjects: 0
Study: 1090417

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate cream
Number of subjects: 34

Group type: COMPARATOR
Intervention: Clobetasol propionate ointment
Number of subjects: 34
Study: 31171523

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Number of subjects: 675

Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin (large artery atherosclerosis)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin (large artery atherosclerosis)
Number of subjects: 675
Study: 28427362

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (MRT)
Number of subjects: 1239

Group type: COMPARATOR
Intervention: Higher, fixed-dose budesonide plus as-needed terbutaline
Number of subjects: 1239
Study: 26301864

Group type: EXPERIMENTAL
Intervention: Connect intervention (Internet-based sessions)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (general educational video)
Number of subjects: 193
Study: 25053261

Group type: EXPERIMENTAL
Intervention: Celebrating the strengths of black youth (CSBY) intervention, consisting of 10 in-person group sessions
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Celebrating the strengths of black youth (CSBY) intervention
Number of subjects: 73

Group type: COMPARATOR
Intervention: Waitlist control (WLC) group
Number of subjects: 73
Study: 22395731

Group type: EXPERIMENTAL
Intervention: Dopamine agonist (levodopa)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Dopamine antagonist (haloperidol)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 19157723

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Number of subjects: 854

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 854
Study: 17180268

Group type: EXPERIMENTAL
Intervention: Aerosolized bupivacaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Local bupivacaine in the bladder bed
Number of subjects: 80

Group type: COMPARATOR
Intervention: Aerosolized normal saline
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 16087986

Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyramethamine (SP)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Vitamin A (100,000 or 200,000 IU depending on age)
Number of subjects: 141
Study: 12123540

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily
Number of subjects: 12637

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg daily
Number of subjects: 12637
Study: 10201413

Group type: EXPERIMENTAL
Intervention: Pramipexole (n=34)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (n=44)
Number of subjects: 78
Study: 7778957

Group type: EXPERIMENTAL
Intervention: Intravenous ceftizoxime sodium (1 g every 12 hours) or ceftriaxone sodium (1 g every 24 hours) followed by oral cefixime (400 mg every 24 hours) after meeting criteria for switch.
Number of subjects: 120
Study: 2181111

Group type: EXPERIMENTAL
Intervention: BANA hydrolysis assay
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: ELISA for antibodies to B. gingivalis and T. denticola
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Reagent card format for BANA hydrolysis
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both diagnostic procedures (ELISA and BANA hydrolysis)
Number of subjects: 117
Study: 7000171

Group type: EXPERIMENTAL
Intervention: 3% acyclovir
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5% idoxuridine (IDU)
Number of subjects: 60
Study: 31823309

Group type: EXPERIMENTAL
Intervention: 15-hour integrated curriculum on conflicts of interest and shared decision-making
Number of subjects: 63

Group type: COMPARATOR
Intervention: Course manual adapted from teaching as usual
Number of subjects: 63
Study: 31934993

Group type: EXPERIMENTAL
Intervention: BCD-132 (100 to 1000 mg intravenous infusion)
Number of subjects: 24
Study: 28950697

Group type: EXPERIMENTAL
Intervention: Perceived barriers towards breast cancer screening
Number of subjects: 816
Study: 24237929

Group type: EXPERIMENTAL
Intervention: Topical diltiazem cream
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 23704673

Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone (M+R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin alone (M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin plus lifestyle (M+L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (M+R, M, M+L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adiposity measures (BMI, waist circumference, abdominal height, fat)
Number of subjects: 0
Study: 21585061

Group type: EXPERIMENTAL
Intervention: Pricking bleeding therapy (applied to specific points on the thumb and auricular helix), once daily for 7 days.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasonic atomizing inhalation (UAI), once daily for 7 days for 15 minutes.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pricking bleeding therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasonic atomizing inhalation (UAI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 19532041

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (add-on treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monotherapy antiepileptic drugs (head-to-head trials)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pseudoplacebo
Number of subjects: 0
Study: 16904458

Group type: EXPERIMENTAL
Intervention: Topical alprostadil cream 100 microg
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: Topical alprostadil cream 200 microg
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: Topical alprostadil cream 300 microg
Number of subjects: 1732

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: Topical alprostadil cream (all doses)
Number of subjects: 1732
Study: 14990632

Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg/d
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/d
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1093
Study: 10619583

Group type: EXPERIMENTAL
Intervention: losartan (50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: valsartan (80 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: irbesartan (150 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 7488395

Group type: EXPERIMENTAL
Intervention: Evaporimeter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tewameter
Number of subjects: 0
Study: 2042654

Group type: EXPERIMENTAL
Intervention: Calcium citrate, 950 mg four times a day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Aluminum hydroxide (2.4 g/d)
Number of subjects: 8
Study: 7200859

Group type: EXPERIMENTAL
Intervention: Vincristin, adriamycin and cis‐platinum (n = 21)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ifosfamide and cis‐platinum (n = 22)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ifosfamide and cis‐platinum
Number of subjects: 43
Study: 31451360

Group type: EXPERIMENTAL
Intervention: Self-administered web-based decision aid
Number of subjects: 2702
Study: 30843441

Group type: EXPERIMENTAL
Intervention: Transvenous embolisation (with or without transarterial embolisation)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Transarterial embolisation alone
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Transvenous embolisation
Number of subjects: 76
Study: 29063521

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Health enhancement program (HEP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Baseline amygdala activation
Number of subjects: 80

Group type: COMPARATOR
Intervention: MBCT and HEP
Number of subjects: 80
Study: 24216046

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training seven times per week for at least 2 weeks before surgery
Number of subjects: 0
Study: 23148822

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity exercise intervention (ST+EX)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Health and wellness education intervention (ST+CTRL)
Number of subjects: 150
Study: 20600693

Group type: EXPERIMENTAL
Intervention: Click train
Number of subjects: 0
Study: 17585210

Group type: EXPERIMENTAL
Intervention: Sevoflurane at a concentration of 2.0% maintained for at least 10 min, with adjustments based on patient movement (6-8% induction, 100% oxygen).
Number of subjects: 90
Study: 16130190

Group type: EXPERIMENTAL
Intervention: 1000 mg mycophenolate mofetil (MMF) twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: FK506
Number of subjects: 0

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MPA
Number of subjects: 0
Study: 12165821

Group type: EXPERIMENTAL
Intervention: Heated and humidified gas
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard carbon dioxide (CO2) gas (control)
Number of subjects: 20
Study: 10434353

Group type: EXPERIMENTAL
Intervention: Dexamethasone alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melphalan-dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone-interferon alpha
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8537029

Group type: EXPERIMENTAL
Intervention: 0.125% tropicamide with nasolacrimal occlusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.125% tropicamide without nasolacrimal occlusion
Number of subjects: 40
Study: 2209407

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 479

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 479
Study: 6218098

Group type: EXPERIMENTAL
Intervention: Mezlocillin treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study: 31350995

Group type: EXPERIMENTAL
Intervention: Dual therapy (abacavir/lamivudine/dolutegravir)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Triple therapy (abacavir/lamivudine/dolutegravir)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Monotherapy (dolutegravir)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Triple therapy (tenofovir/emtricitabine + a third agent)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: LDR (Low Drug Regimen)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 64
Study: 31501110

Group type: EXPERIMENTAL
Intervention: Text messaging intervention for tobacco cessation
Number of subjects: 57
Study: 28886856

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 28

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 28
Study: 26951842

Group type: EXPERIMENTAL
Intervention: Knowledge-attitude-behaviour health education model
Number of subjects: 86

Group type: COMPARATOR
Intervention: Usual care and general education models
Number of subjects: 86
Study: 25106094

Group type: EXPERIMENTAL
Intervention: Workplace-oriented intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Workplace-oriented intervention (younger subgroup)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (younger subgroup)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Workplace-oriented intervention (older subgroup)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (older subgroup)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Part-time sick leave
Number of subjects: 68
Study: 22257503

Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bobath Concept
Number of subjects: 24
Study: 19232039

Group type: EXPERIMENTAL
Intervention: Nebulized formoterol fumarate inhalation solution (Perforomist, FFIS 20g BID)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Ipratropium and albuterol combined in a metered-dose inhaler (MDI) (Combiventy, IPR-ALB, QID)
Number of subjects: 109
Study: 17925883

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) applied on the hip for nine hours.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 0